Literature DB >> 25265461

Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.

A Salhotra1, N Tsai2, S H Thomas1, T Paris2, P Parker1, S J Forman1, R Nakamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25265461      PMCID： PMC4286488          DOI： 10.1038/bmt.2014.210

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.

Authors:  Isabel Sánchez-Ortega; Octavio Servitje; Montserrat Arnan; Guillermo Ortí; Teresa Peralta; Federico Manresa; Rafael F Duarte
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-07       Impact factor: 5.742

2.  Sjögren-type syndrome after allogeneic bone-marrow transplantation.

Authors:  A A Gratwohl; A A Gratwhol; H M Moutsopoulos; T M Chused; M Akizuki; R O Wolf; J B Sweet; A B Deisseroth
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

3.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

4.  Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

Authors:  G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

5.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Effie W Petersdorf; J Lee Nelson; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; John A Hansen; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2013-04-01       Impact factor: 22.113

6.  A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.

Authors:  George L Chen; Sally Arai; Mary E D Flowers; Joanne M Otani; Jingxin Qiu; Ethan C Cheng; Alex McMillan; Laura J Johnston; Judith A Shizuru; David B Miklos
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

7.  Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.

Authors:  Attilio Olivieri; Michele Cimminiello; Paolo Corradini; Nicola Mordini; Roberta Fedele; Carmine Selleri; Francesco Onida; Francesca Patriarca; Enzo Pavone; Silvia Svegliati; Armando Gabrielli; Paola Bresciani; Roberta Nuccorini; Sara Pascale; Sabrina Coluzzi; Fabrizio Pane; Antonella Poloni; Jacopo Olivieri; Pietro Leoni; Andrea Bacigalupo
Journal:  Blood       Date:  2013-10-23       Impact factor: 22.113

8.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

9.  Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

Authors:  Leonardo Magro; Mohamad Mohty; Benoit Catteau; Valérie Coiteux; Patrice Chevallier; Louis Terriou; Jean-Pierre Jouet; Ibrahim Yakoub-Agha
Journal:  Blood       Date:  2009-03-16       Impact factor: 22.113

10.  Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.

Authors:  Cristina Skert; Francesca Patriarca; Alessandra Sperotto; Michela Cerno; Carla Filì; Francesco Zaja; Raffaella Stocchi; Antonella Geromin; Daniela Damiani; Renato Fanin
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.